 developing treatments for schizophrenia ms addiction  bipolar disorder home contact us site map about us about us about alkermes our company message from the ceo locations leadership management team board of directors collaborations strategic partners products products products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies research  development research  development research  development rd overview our rd approach pipeline technology platforms manufacturing other information clinical trials expanded access responsibility responsibility responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors investors investors corporate overview press releases investor events stock information sec filings annual reports financials snapshot trading statistics other information email alerts news  events news  events news  events press releases media kit careers careers careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer job opportunities jobs overview field sales roles all available roles products home products products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies overview a portfolio of vital products alkermes’ diverse product portfolio reflects our powerful expertise in the development of innovative patientinspired solutions our products are based on proprietary science and technology that provide unique treatment options for patients with debilitating diseases in particular alkermes is focused on drug development for central nervous system cns diseases a therapeutic area where we have a proven track record our aim is to develop new medicines that make significant advances for chronic cns conditions that affect millions of patients such as schizophrenia major depressive disorder and multiple sclerosis click here to learn about our strong pipeline of innovative product candidates other resources pipeline press releases you are now leaving alkermescom about us our company message from the ceo locations management team board of directors strategic partners products products overview aristada® vivitrol® us products using alkermes technologies eu products using alkermes technologies wholesaler and purchasing information research  development rd overview our rd approach pipeline technology platforms manufacturing clinical trials expanded access responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors corporate overview press releases investor events stock information sec filings annual reports snapshot trading statistics email alerts news  events press releases media kit careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer jobs overview field sales roles all available roles  alkermes all rights reserved terms of use privacy policy ﻿ aristada  products  alkermes home contact us site map about us about us about alkermes our company message from the ceo locations leadership management team board of directors collaborations strategic partners products products products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies research  development research  development research  development rd overview our rd approach pipeline technology platforms manufacturing other information clinical trials expanded access responsibility responsibility responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors investors investors corporate overview press releases investor events stock information sec filings annual reports financials snapshot trading statistics other information email alerts news  events news  events news  events press releases media kit careers careers careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer job opportunities jobs overview field sales roles all available roles products home products aristada® products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies aristada® you are now entering the us products page this page is intended for the us audience only aristada® aripiprazole lauroxil extendedrelease injectable suspension is a longacting atypical antipsychotic that is approved by the us food and drug administration fda for the treatment of schizophrenia aristada is available in four dose strengths with oncemonthly dosing  mg  mg  mg a sixweek dosing option  mg and a twomonth dosing option  mg for more information visit wwwaristadacom indication and important safety information for aristada® aripiprazole lauroxil extendedrelease injectable suspension for intramuscular use indication aristada is a prescription medicine given by injection by a healthcare professional and used to treat schizophrenia it is not known if aristada is safe and effective in children under  years of age important safety information elderly people with dementiarelated psychosis are at increased risk of death when treated with antipsychotic medicines including aristada aristada is not for the treatment of people who have lost touch with reality psychosis due to confusion and memory loss dementia   contraindication do not receive aristada if you are allergic to aripiprazole or any of the ingredients in aristada allergic reactions to aripiprazole have ranged from rash hives and itching to anaphylaxis which may include difficulty breathing tightness in the chest and swelling of the mouth face lips or tongue aristada may cause serious side effects including stroke cerebrovascular problems in elderly people that can lead to death neuroleptic malignant syndrome nms a rare and serious condition that can lead to death call your healthcare provider right away if you have some or all of the following symptoms of nms high fever stiff muscles confusion sweating changes in pulse heart rate and blood pressure uncontrolled body movements tardive dyskinesia aristada may cause movements that you cannot control in your face tongue or other body parts tardive dyskinesia may not go away even if you stop receiving aristada tardive dyskinesia may also start after you stop receiving aristada problems with your metabolism such as high blood sugar hyperglycemia increases in blood sugar can happen in some people who receive aristada extremely high blood sugar can lead to coma or death if you have diabetes or risk factors for diabetes such as being overweight or a family history of diabetes your healthcare provider should check your blood sugar before you start receiving aristada and during your treatment call your healthcare provider if you have any of these symptoms of high blood sugar while receiving aristada feel very thirsty need to urinate more than usual feel very hungry feel weak or tired feel sick to your stomach feel confused or your breath smells fruity increased fat levels cholesterol and triglycerides in your blood weight gain you and your healthcare provider should check your weight regularly gambling urges and other uncontrollable compulsive behaviors there is the possibility that you may have strong urges to gamble shop have sex binge eat or have other uncontrollable strong urges if you or your family members notice that you are having uncontrollable urges talk to your healthcare provider decreased blood pressure orthostatic hypotension you may feel lightheaded or faint when you rise too quickly from a sitting or lying position falls because antipsychotic medicines like aristada may cause drowsiness or dizziness when standing you may be at risk for falls and related injurieslow white blood cell count seizures convulsions problems controlling your body temperature so that you feel too warm do not become too hot or dehydrated while you receive aristada do not exercise too much in hot weather stay inside in a cool place if possible stay out of the sun do not wear too much clothing or heavy clothing drink plenty of water difficulty swallowing the most common side effect of aristada includes feeling like you need to move to stop unpleasant feelings in your legs restless leg syndrome or akathisia these are not all the possible side effects of aristada tell your healthcare provider if you have any side effect that bothers you or does not go away do not drive operate machinery or do other dangerous activities until you know how aristada affects you aristada may make you feel drowsy do not drink alcohol while you receive aristada before receiving aristada tell your healthcare provider about all of your medical conditions including if you have never taken abilify® abilify maintena® or any aripiprazole product before have diabetes or high blood sugar or a family history of diabetes or high blood sugar your healthcare provider should check your blood sugar before you start receiving aristada and during your treatment have or had seizures convulsions have or had low or high blood pressure have or had heart problems or a stroke have or had a low white blood cell count have problems that may affect you receiving an injection in your buttocks or your arm are pregnant or plan to become pregnant it is not known if aristada will harm your unborn baby if you become pregnant while taking aristada talk to your healthcare provider about registering with the national pregnancy registry for atypical antipsychotics you can register by calling  or visit httpwomensmentalhealthorgclinicalandresearchprogramspregnancyregistry are breastfeeding or plan to breastfeed aristada can pass into your breast milk it is not known if it may harm your baby talk to your healthcare provider about the best way to feed your baby if you receive aristada tell your healthcare provider about all the medicines you take including prescription and overthecounter medicines vitamins and herbal supplements aristada and other medicines may affect each other causing possible serious side effects do not start or stop any medicines while receiving aristada without talking to your healthcare provider first if you have any questions about your health or medicines talk to your healthcare provider you are encouraged to report all side effects of prescription drugs to the fda visit wwwfdagovmedwatch or call fda please see full prescribing information including boxed warning and medication guide alkermes is a registered trademark of alkermes inc and aristada® and logo are registered trademarks of alkermes pharma ireland limited used by alkermes inc under license abilify® and abilify maintena® are registered trademarks of otsuka pharmaceutical company this page is intended for the us audience only you are now leaving alkermescom about us our company message from the ceo locations management team board of directors strategic partners products products overview aristada® vivitrol® us products using alkermes technologies eu products using alkermes technologies wholesaler and purchasing information research  development rd overview our rd approach pipeline technology platforms manufacturing clinical trials expanded access responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors corporate overview press releases investor events stock information sec filings annual reports snapshot trading statistics email alerts news  events press releases media kit careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer jobs overview field sales roles all available roles  alkermes all rights reserved terms of use privacy policy ﻿ vivitrol  products  alkermes home contact us site map about us about us about alkermes our company message from the ceo locations leadership management team board of directors collaborations strategic partners products products products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies research  development research  development research  development rd overview our rd approach pipeline technology platforms manufacturing other information clinical trials expanded access responsibility responsibility responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors investors investors corporate overview press releases investor events stock information sec filings annual reports financials snapshot trading statistics other information email alerts news  events news  events news  events press releases media kit careers careers careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer job opportunities jobs overview field sales roles all available roles products home products vivitrol® products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies vivitrol® you are now entering the us products page this page is intended for the us audience only vivitrol® naltrexone for extendedrelease injectable suspension is a oncemonthly medication for the treatment of alcohol dependence as well as for the prevention of relapse to opioid dependence following opioid detoxification vivitrol is the first and only nonnarcotic nonaddictive oncemonthly medication approved for the treatment of opioid dependence treatment with vivitrol should be part of a comprehensive management program that includes psychosocial support for more information visit wwwvivitrolcom important safety information for vivitrol® naltrexone for extendedrelease injectable suspension important safety information what is vivitrol® vivitrol naltrexone for extendedrelease injectable suspension is a prescription injectable medicine used to treat alcohol dependence you should stop drinking before starting vivitrol prevent relapse to opioid dependence after opioid detox you must stop taking opioids or other opioidcontaining medications before starting vivitrol vivitrol must be used with other alcohol or drug recovery programs such as counseling vivitrol may not work for everyone and has not been studied in children do not take vivitrol if you are still using or still have any symptoms of physical withdrawal due to dependence on opioid street drugs or opioidcontaining medicines have opioid withdrawal symptoms are allergic to naltrexone or any of the ingredients in vivitrol or the liquid used to mix vivitrol see the medication guide for more information about opioid withdrawal and the ingredients in vivitrol and the liquid used to mix it what is the most important information i should know about vivitrol vivitrol can cause serious side effects including risk of opioid overdose using opioids even in amounts that you used before vivitrol treatment can lead to accidental overdose serious injury coma or death to avoid accidental overdose do not take large amounts of opioids or try to overcome the opioidblocking effects of vivitrol do not use opioids in amounts that you used before vivitrol treatment you may even be more sensitive to lower amounts of opioids after detox when your next vivitrol dose is due if you miss a dose of vivitrol after you stop vivitrol treatment get emergency medical help right away if you have trouble breathing become very drowsy with slowed breathing have slow shallow breathing feel faint dizzy confused or have other unusual symptoms severe reactions at the injection site vivitrol may cause severe injection site reactions including tissue death some injection site reactions have required surgery call your doctor right away if you notice any of the following at your injection site intense pain the area feels hard swelling lumps blisters an open wound a dark scab tell your doctor about any injection site reaction that concerns you gets worse overtime or does not get better by two weeks after the injection sudden opioid withdrawal to avoid sudden opioid withdrawal you must stop taking any opioids or opioidcontaining medications including buprenorphine or methadone for at least  to  days before starting vivitrol if your doctor decides that you don’t need to complete detox first he or she may give you vivitrol in a medical facility that can treat sudden opioid withdrawal sudden opioid withdrawal can be severe and may require hospitalization liver damage or hepatitis naltrexone the active ingredient in vivitrol can cause liver damage or hepatitis tell your doctor if you have any of the following symptoms of liver problems during vivitrol treatment stomach area pain lasting more than a few days yellowing of the whites of your eyes dark urine tiredness other possible side effects vivitrol can cause other serious side effects such as depressed mood – sometimes this leads to suicide or suicidal thoughts and behavior tell those closest to you that you are taking vivitrol you or those closest to you should call your doctor right away if you become depressed or have any new or worsening depression symptoms allergic pneumonia – tell your healthcare provider if you have shortness of breath wheezing or a cough that doesn’t go away serious allergic reactions – get medical help immediately if you have a skin rash swelling of your face eyes mouth or tongue trouble breathing or wheezing chest pain or are feeling dizzy or faint common side effects of vivitrol include nausea tiredness headache dizziness vomiting decreased appetite painful joints and muscle cramps in addition common side effects in people taking vivitrol for opioid dependence also include cold symptoms trouble sleeping and toothache these are not all of the side effects of vivitrol for more information ask your healthcare provider tell your doctor right away if you have any side effect that does not go away see the attached medication guide for more information call your doctor for medical advice about any side effects you are encouraged to report negative side effects to the fda visit wwwfdagovmedwatch or call fda this page is intended for the us audience only you are now leaving alkermescom about us our company message from the ceo locations management team board of directors strategic partners products products overview aristada® vivitrol® us products using alkermes technologies eu products using alkermes technologies wholesaler and purchasing information research  development rd overview our rd approach pipeline technology platforms manufacturing clinical trials expanded access responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors corporate overview press releases investor events stock information sec filings annual reports snapshot trading statistics email alerts news  events press releases media kit careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer jobs overview field sales roles all available roles  alkermes all rights reserved terms of use privacy policy ﻿ our cns drug development pipeline product candidates  alkermes home contact us site map about us about us about alkermes our company message from the ceo locations leadership management team board of directors collaborations strategic partners products products products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies research  development research  development research  development rd overview our rd approach pipeline technology platforms manufacturing other information clinical trials expanded access responsibility responsibility responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors investors investors corporate overview press releases investor events stock information sec filings annual reports financials snapshot trading statistics other information email alerts news  events news  events news  events press releases media kit careers careers careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer job opportunities jobs overview field sales roles all available roles research  development home research  development pipeline research  development rd overview our rd approach pipeline technology platforms manufacturing other information clinical trials expanded access pipeline robust product pipeline our rich pipeline of product candidates demonstrates our leadership in drug development for central nervous system cns diseases a therapeutic area where we have a proven track record of success backed by decades of experience we are able to streamline clinical development time and substantially increase the probability of latestage product success the proof is in our substantial pipeline and its potential to have a unique and positive impact for patients transition from physical dependence on opioids to vivitrol® learn more about our portfolio of innovative products you are now leaving alkermescom about us our company message from the ceo locations management team board of directors strategic partners products products overview aristada® vivitrol® us products using alkermes technologies eu products using alkermes technologies wholesaler and purchasing information research  development rd overview our rd approach pipeline technology platforms manufacturing clinical trials expanded access responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors corporate overview press releases investor events stock information sec filings annual reports snapshot trading statistics email alerts news  events press releases media kit careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer jobs overview field sales roles all available roles  alkermes all rights reserved terms of use privacy policy ﻿ alkermes key eu pharmaceutical manufacturing products  alkermes home contact us site map about us about us about alkermes our company message from the ceo locations leadership management team board of directors collaborations strategic partners products products products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies research  development research  development research  development rd overview our rd approach pipeline technology platforms manufacturing other information clinical trials expanded access responsibility responsibility responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors investors investors corporate overview press releases investor events stock information sec filings annual reports financials snapshot trading statistics other information email alerts news  events news  events news  events press releases media kit careers careers careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer job opportunities jobs overview field sales roles all available roles products home products eu products using alkermes technologies products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies eu products using alkermes technologies all product information provided is intended for the european union audience only these products may not be available in all member states of the eu or in countries outside the eu or may be available under a different trademark in different strengths or for different indications countries outside the eu may have different regulatory requirements that would call for different information to be available products using alkermes technologies we have granted licenses under our proprietary technologies to enable third parties to develop commercialize and in some cases manufacture products for which we receive royalties andor manufacturing revenues such arrangements in the european union include the following bydureon® fampyra® risperdal consta® trevicta® xeplion® risperdal consta trevicta and xeplion janssen products utilize alkermes’ proprietary extendedrelease microsphere technology proprietary technology and proprietary nanoparticle injectable extendedrelease technology respectively bydureon® is a registered trademark of astrazeneca pharmaceuticals lp fampyra® is a registered trademark of acorda therapeutics inc risperdal consta® trevicta® and xeplion® are registered trademarks of johnson  johnson this page is intended for the eu audience only you are now leaving alkermescom about us our company message from the ceo locations management team board of directors strategic partners products products overview aristada® vivitrol® us products using alkermes technologies eu products using alkermes technologies wholesaler and purchasing information research  development rd overview our rd approach pipeline technology platforms manufacturing clinical trials expanded access responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors corporate overview press releases investor events stock information sec filings annual reports snapshot trading statistics email alerts news  events press releases media kit careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer jobs overview field sales roles all available roles  alkermes all rights reserved terms of use privacy policy alkermes company  wikipedia alkermes company from wikipedia the free encyclopedia jump to navigation search alkermes plc type public nasdaq alks industry biotechnology headquarters dublin ireland key people richard pops ceo revenue us million operating income us million net income us million total assets us million total equity us million number of employees  website wwwalkermescom alkermes plc is a biopharmaceutical company that focuses on central nervous system cns diseases the company is the result of a merger in september  between alkermes inc and elan drug technologies edt the former drug formulation and manufacturing division of élan corporation plc the company is headquartered in dublin and has an rd center in waltham massachusetts and manufacturing facilities in athlone ireland and wilmington ohio productsedit alkermes has more than  commercial drug products and candidates that address serious and chronic diseases such as addiction schizophrenia diabetes and depression among these products five are primary to the company risperidone longacting injection generic for risperdal consta for schizophrenia and bipolar  disorder paliperidone palmitate generic for invega sustenna in the us xeplion in europe for schizophrenia aminopyridine generic for ampyra in the us fampyra in europe to improve walking in patients with multiple sclerosis naltrexone for extendedrelease injectable suspension generic for vivitrol for alcohol and opioid dependence and exenatide extendedrelease for injectable suspension generic for bydureon for the treatment of type  diabetes bydureon is a onceweekly extendedrelease form of the drug exenatide byetta and was developed through a partnership between amylin pharmaceuticals alkermes and eli lilly it is approved in europe and the us alks a κopioid receptor antagonist is a nextgeneration novel antidepressant which is under development by alkermes for treatmentresistant depression referencesedit  a b robert weisman  may  alkermes to buy irish drug maker boston globe retrieved  october    alkermes alks quarterly report wikiinvest  retrieved  october    alkermes reels in elans drug technology business forbescom  may  retrieved  october    zacks equity research “positive data on risperdal consta” yahoo finance march    john m grohol “risperdal consta approved for bipolar” psychcentralcom may    cole petrochko “fda okays first monthly antipsychotic drug” medpage today august    matt jarzemsky “johnson  johnson gets european approval for schizophrenia shot” the wall street journal march    susan jeffrey “fda approves dalfampridine to improve walking in multiple sclerosis” medscape medical news january    toni clarke “europe backs acorda biogen drug in change of tack” reuters may    miranda hitti “fda oks new drug to treat alcoholism” webmd april    rita rubin “fda oks vivitrol to treat heroin narcotic addictions” usa today october    denise mann weekly shot gets fda nod for type  diabetes webmd january    harrison charlotte  trial watch opioid receptor blocker shows promise in phase ii depression trial nature reviews drug discovery   – issn  pmid  doinrd  v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlealkermescompanyoldid categories pharmaceutical companies of irelandcompanies in the nasdaq biotechnology indexcompanies based in dublin citycompanies listed on nasdaqlife sciences industry navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view ﻿ alkermes – a global biopharmaceutical company home contact us site map about us about us about alkermes our company message from the ceo locations leadership management team board of directors collaborations strategic partners products products products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies research  development research  development research  development rd overview our rd approach pipeline technology platforms manufacturing other information clinical trials expanded access responsibility responsibility responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors investors investors corporate overview press releases investor events stock information sec filings annual reports financials snapshot trading statistics other information email alerts news  events news  events news  events press releases media kit careers careers careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer job opportunities jobs overview field sales roles all available roles science with a purpose alkermes applies its scientific expertise and technological knowhow to develop innovative medicines designed to help patients with serious chronic conditions better manage their disease our company latest news alkermes to host conference call to discuss second quarter  financial results read more alkermes announces positive preliminary topline results from phase  antipsychotic efficacy study of alks  for treatment of schizophrenia read more alkermes announces initiation of study  for alks  for treatment of major depressive disorder read more investors learn more pipeline see our approach working at alkermes join our team you are now leaving alkermescom about us our company message from the ceo locations management team board of directors strategic partners products products overview aristada® vivitrol® us products using alkermes technologies eu products using alkermes technologies wholesaler and purchasing information research  development rd overview our rd approach pipeline technology platforms manufacturing clinical trials expanded access responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors corporate overview press releases investor events stock information sec filings annual reports snapshot trading statistics email alerts news  events press releases media kit careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer jobs overview field sales roles all available roles  alkermes all rights reserved terms of use privacy policy alkermes plc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports alkermes plc  product pipeline review   alkermes plc  product pipeline review   wgr  october  global  pages global markets direct description table of content sample report enquiry before buy related reports alkermes plc  product pipeline review  summaryglobal markets direct’s ‘alkermes plc  product pipeline review  ’ provides an overview of the alkermes plc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of alkermes plc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of alkermes plc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of alkermes plc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the alkermes plc’s pipeline productsreasons to buy evaluate alkermes plc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of alkermes plc in its therapy areas of focus identify new drug targets and therapeutic classes in the alkermes plc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of alkermes plc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of alkermes plc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of alkermes plc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures alkermes plc snapshot alkermes plc overview key information key facts alkermes plc  research and development overview key therapeutic areas alkermes plc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  partnered products partnered productscombination treatment modalities alkermes plc  pipeline products glance alkermes plc  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities alkermes plc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities alkermes plc  early stage pipeline products preclinical productscombination treatment modalities alkermes plc  drug profiles aripiprazole lauroxil product description mechanism of action rd progress samidorphan  buprenorphine hydrochloride product description mechanism of action rd progress samidorphan  olanzapine product description mechanism of action rd progress alks product description mechanism of action rd progress alks product description mechanism of action rd progress samidorphan product description mechanism of action rd progress methylsamidorphan  opioid analgesic product description mechanism of action rd progress olanzapine er product description mechanism of action rd progress rdb product description mechanism of action rd progress alkermes plc  pipeline analysis alkermes plc  pipeline products by target alkermes plc  pipeline products by route of administration alkermes plc  pipeline products by molecule type alkermes plc  pipeline products by mechanism of action alkermes plc  recent pipeline updates alkermes plc  dormant projects alkermes plc  discontinued pipeline products discontinued pipeline product profiles insulin human rhfsh samidorphan teriparatide alkermes plc  company statement alkermes plc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesalkermes plc key information alkermes plc key facts alkermes plc  pipeline by indication  alkermes plc  pipeline by stage of development  alkermes plc  monotherapy products in pipeline  alkermes plc  combination treatment modalities in pipeline  alkermes plc  partnered products in pipeline  alkermes plc  partnered products combination treatment modalities  alkermes plc  preregistration  alkermes plc  phase iii  alkermes plc  phase ii  alkermes plc  phase i  alkermes plc  preclinical  alkermes plc  pipeline by target  alkermes plc  pipeline by route of administration  alkermes plc  pipeline by molecule type  alkermes plc  pipeline products by mechanism of action  alkermes plc  recent pipeline updates  alkermes plc  dormant developmental projects alkermes plc  discontinued pipeline products  alkermes plc other locations alkermes plc subsidiaries list of figuresalkermes plc  pipeline by top  indication  alkermes plc  pipeline by stage of development  alkermes plc  monotherapy products in pipeline  alkermes plc  combination treatment modalities in pipeline  alkermes plc  partnered products in pipeline  alkermes plc  pipeline by top  target  alkermes plc  pipeline by top  route of administration  alkermes plc  pipeline by top  molecule type  alkermes plc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send alkermes plc and china biologic products inc head to head compare newscmlvizcom menu share  news home   apple   facebook   tesla   amazon   google   archive   our authors   contact alkermes plc nasdaqalks  china biologic products inc nasdaqcbpo  alks cbpo compare alkermes plc versus china biologic products inc head to head compare date published  this is a head to head compare of alkermes plc nasdaqalks and china biologic products inc nasdaqcbpo  we will compare the two companies on revenue growth earnings revenue per employee operating margins free cash flow and valuation the head to head compare assigns  points in total before we dive into the analysis we will look at the stock returns for each company over the last three months six months and the last year the stock returns do not impact the head to head compare scores which are focused on the fundamentals of each company but ultimately stock returns are are still a critical piece to a full analysis and compare stock returns symbol months months oneyear fundamentals alks    cbpo    china biologic products inc has a substantially higher fundamental rating then alkermes plc which has an impact on the headtohead comparison the cml star rating is an objective quantifiable measure of a companys operating and financial condition the rating is computed by measuring numerous elements of the companys current financial data and their associated changes over time now lets dive into the two companies to compare them ➤ income statement first we turn to the income statement and compare revenue earnings and revenue per employee for both companies we note that simple revenue comparisons do not impact the rating ↪ alkermes plc has substantially higher revenue in the last year than china biologic products inc although both companies are still relatively small raw revenue comps do not affect the head to head ratingrevenue↪ cbpo is showing a profit while alks has negative earnings over the last yearnet income↪ alks generates massively larger revenue per employee  than cbpo revenue per employee  millions ➤ margins next we create some derived metrics to compare the the amount of revenue earned per dollar of expense and the amount of free cash flow earned per dollar of revenue margins are one of the fairest ways to compare companies since they remove some of the bias of large versus small numbers ↪ china biologic products inc generates  in revenue for every  of expense while alkermes plc generates an operating loss with just  in revenue per  of expenserevenue per dollar of expense↪ cbpo generates  in levered free cash flow for every  of revenue while alks generates a cash flow loss of  per  of revenuefree cash flow per dollar of revenue ➤ growth finally we compare the financial metrics related to growth revenue growth rates and price to sales ↪ both companies are growing revenue alkermes plc is growing revenue faster than china biologic products inc but not by a notable amountrevenue growth↪ for every  in revenue the stock market prices in  in market cap for alks and  in market cap for cbpoprice to sales china biologic products inc nasdaqcbpo defeats alkermes plc nasdaqalks   to  x the worlds best options backtester    watch the video now please read the legal disclaimers belowlegal the information contained on this site is provided for general informational purposes as a convenience to the readers the materials are not a substitute for obtaining professional advice from a qualified person firm or corporation consult the appropriate professional advisor for more complete and current information capital market laboratories the company does not engage in rendering any legal or professional services by placing these general informational materials on this website the company specifically disclaims any liability whether based in contract tort strict liability or otherwise for any direct indirect incidental consequential or special damages arising out of or in any way connected with access to or use of the site even if we have been advised of the possibility of such damages including liability in connection with mistakes or omissions in or delays in transmission of information to or from the user interruptions in telecommunications connections to the site or viruses the company make no representations or warranties about the accuracy or completeness of the information contained on this website any links provided to other server sites are offered as a matter of convenience and in no way are meant to imply that the company endorses sponsors promotes or is affiliated with the owners of or participants in those sites or endorse any information contained on those sites unless expressly stated alkermes plc alkso company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile alkermes plc alkso related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse alkso on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description alkermes plc incorporated on may   is a biopharmaceutical company the company is engaged in the researching developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas the company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system cns disorders such as schizophrenia depression addiction and multiple sclerosis ms its products include aristada vivitrol invega sustenna xeplion invega trinza trevicta risperdal consta ampyra fampyra bydureon aripiprazole lauroxil alks  alks  alks  alks  alks  and alks the companys product platforms include injectable extended release microsphere technology linkerx technology nanocrystal technology and oral controlled release ocr technology the companys subsidiaries include alkermes ireland holdings limited daravita pharma ireland limited daravita limited alkermes science four limited alkermes science five limited alkermes science six limited alkermes pharma ireland limited alkermes us holdings inc alkermes inc alkermes controlled therapeutics inc alkermes europe ltd alkermes finance ireland limited alkermes finance ireland no  limited alkermes finance ireland no  limited and alkermes finance sa rlaristada is an extendedrelease intramuscular injectable suspension for the treatment of schizophrenia it utilizes its linkerx technology it is a prodrug once in the body it is converted by enzymemediated hydrolysis to nhydroxymethyl aripiprazole which is then hydrolyzed to aripiprazole it is the antipsychotic with oncemonthly and sixweek dosing options to deliver and maintain therapeutic levels of medication in the body it has three dosing options  milligrams mg  mg and  mg and is packaged in a prefilled product format it develops manufactures and commercializes it in the united statesvivitrol is a once monthly nonaddictive and injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence following opioid detoxification it uses its polymer based microsphere injectable extended release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks it develops manufactures and commercializes vivitrol in the united states russia and other countriesinvega sustennaxeplion invega trinzatrevicta and risperdal consta are antipsychotics invega sustenna is for the treatment of schizophrenia and for the treatment of schizoaffective disorder as either a monotherapy or adjunctive therapy invega sustennaxeplion extendedrelease injectable suspension is for the treatment of schizophrenia and is marketed and sold under the trade name xeplion invega sustennaxeplion uses its nanoparticle injectable extendedrelease technology to increase the rate of dissolution and enable the formulation of an aqueous suspension for oncemonthly intramuscular administrationinvega trinza is an antipsychotic injection for the treatment of schizophrenia used in people treated with invega sustenna invega trinza is the schizophrenia treatment to be taken once every three months trevicta is used for the maintenance treatment of schizophrenia in adult patients clinically stable on xeplion risperdal consta is approved for the treatment of schizophrenia and as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar i disorder it uses its polymerbased microsphere injectable extendedrelease technology to deliver and maintain therapeutic medication levels in the body through just one intramuscular injection every two weeksampyra dalfampridinefampyra fampridine is the treatment approved across europe asia and the americas to develop walking in adults with ms having walking disability extendedrelease dalfampridine tablets are marketed and sold by acorda in the united states under the trade name ampyra and by biogen ma inc outside the united states under the trade name fampyra bydureon exenatide extendedrelease for injectable suspension is approved for the treatment of type  diabetes bydureon a onceweekly formulation of exenatide uses its polymerbased microsphere injectable extendedrelease technology bydureon pen  mg a prefilled single use pen injector that contains the same formulation and dose as the original bydureon single dose tray is available in the united states certain countries in the european union and japanaripiprazole lauroxil which is an intramuscular injectable antipsychotic available as aristada with once monthly and sixweek dosing options for the treatment of schizophrenia is in development with a twomonth dosing interval alks  is a oncedaily oral sublingual investigational medicine with a mechanism of action in development for the adjunctive treatment of major depressive disorder mdd in patients with a response to standard antidepressant therapies alks  consists of samidorphan in combination with buprenorphinealks  is an oral investigational medicine designed as an antipsychotic for the treatment of schizophrenia alks  consists of samidorphan in combination with the established antipsychotic drug olanzapine which is available under the name zyprexa alks  is designed to provide the ability of olanzapine and a differentiated safety profile from olanzapine with weight and metabolic properties and to have utility in the treatment of schizophrenia in patients with cooccurring alcohol use disorder alks  is an oral investigational monomethyl fumarate mmf molecule in development for the treatment of msalks  is designed to enable healthcare providers transition patients from physical dependence on opioids to initiation with vivitrol alks  is an investigational regimen of ascending doses of oral naltrexone administered in conjunction with ancillary medications during a sevenday treatment period prior to first vivitrol injection alks  is its selective effector cell activator seca that is designed to harness a patients immune system to activate and increase the number of tumor killing immune cells seca proteins target immune cells to avoid expansion of immune regulatory cells which interfere with the antitumor response seca molecules are engineered using its fusion protein technology platform to modulate the natural mechanism of action of a biologic product alks  is an oral investigational medicine that has a multivalent mechanism of action that acts on receptors in the brain involved in several cns diseases including agitation in alzheimers disease mdd and othersthe injectable extended release microsphere technology allows to encapsulate small molecule pharmaceuticals peptides and proteins in microspheres made of common medical polymers the technology is designed to enable formulations of pharmaceuticals by providing controlled extended release of drugs over time the linkerx technology platform is designed to enable the creation of extended release injectable versions of antipsychotic therapies and are also useful in other disease areas in which extended duration of action provides therapeutic benefits the technology uses linker tail chemistry to create new molecular entities derived from known agentsthe nanocrystal technology is applicable to water soluble compounds and involves formulating and stabilizing drugs into particles that are nanometers in size a drug in nanocrystal form can be incorporated into a range of common dosage forms and administration routes including tablets capsules inhalation devices and sterile forms for injection its ocr technologies are used to formulate develop and manufacture oral dosage forms of pharmaceutical products that control the release characteristics of standard dosage forms its ocr platform includes technologies for pharmacokinetic profiles including spheroidal oral drug absorption system sodas technology chronotherapeutic oral drug absorption system codas technology intestinal protective drug absorption system ipdas technology and the matrix drug absorption system mxdas drug absorption systemsodas technology involves producing spherical beads of  millimeter mm to  mm in diameter containing drug plus excipients and coated with product specific modified release polymers codas technology enables the delayed onset of drug release incorporating the use of specific polymers resulting in a drug release profile that complements circadian patterns ipdas technology conveys gastrointestinal protection by a dispersion of drug in a manner through the use of controlled release beads compressed into a tablet form mxdas technology formulates the drug in a hydrophilic matrix and incorporates one or more hydrophilic matrix forming polymers into a solid oral dosage form which controls the release of drug through a process of diffusion and erosion in the gastrointestinal tractthe company competes with eli lilly  company otsuka pharmaceutical co ltd indivior plc biodelivery sciences braeburn pharmaceuticals orexo us inc novo nordisk as biogen ma inc bayer healthcare pharmaceuticals teva pharmaceutical industries ltd emd serono inc novartis ag and sanofi aventis » full overview of alkso company address alkermes plc connaught hse  burlington roaddublin      p  company web links home page officers  directors name compensation richard pops  shane cooke  james frates  kathryn biberstein  elliot ehrich  » more officers  directors alkermes plc news briefalkermes announces positive preliminary topline results jun   briefalkermes announces initiation of study  for alks  jun   briefalkermes initiates phase  study of alks  in young adult patients jun   briefalkermes ceo richard pops  total compensation was  mln vs  mln in  apr   briefalkermes q nongaap earnings per share  feb   » more alkso news related topics stocksstock screenerhealthcarebiotechnology  medical research stockflare alks stock price  alkermes plc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers fcx  nem  rrc  cat  stx  ipg  mu  wat  latest newsall times eastern p updated does your child have a question there’s a smart toy for that p updated house votes to prevent disgruntled customers from being able to sue their bank p updated one depressing reason millions of people are locked out of the american dream p updated what everyone can learn from jared kushner’s ad hoc approach to meetings p one version of gop healthcare bills fails in senate vote p updated george clooney and angelina jolie’s directorial projects could be the most soughtafter tickets at tiff p john mccain gives trump a win then gives senate an earful p updated paypal earnings partnerships help but are benefits already priced in p updated amd puts intel in the crosshairs with fastandcheap threadripper chip p amd earnings give investors what they wanted now it must deliver to be replaced home investing quotes stocks united states alks overview compare quotes stock screener earnings calendar sectors nasdaq alks us nasdaq join td ameritrade find a broker alkermes plc watchlist createalksalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones opinion what to do when your biotechnology stock gets hit by takeover rumors may   at  pm et by michael brush ‘super bowl’ of health care has questions about trump and drug prices but no answers jan   at  am et by emma court alkermes upgraded to overweight from neutral at jp morgan oct   at  am et by tomi kilgore alkermes stock price target raised to  from  at jp morgan oct   at  am et by tomi kilgore alkermes shares soar more than  after depression drug results oct   at  pm et by wallace witkowski breaking alkermes shares surge  after promising depression drug data oct   at  pm et by wallace witkowski opinion biotech stocks have plenty of catalysts around the corner sep   at  pm et by michael brush alkermes shares plunge after drug misses trial goals jan   at  am et by emma court alkermes stock plunges  premarket after disappointing drug trial results jan   at  am et by tomi kilgore charting the sp ’s precarious posture dec   at  am et by michael ashbaugh opinion how to stop pfizer’s fauxirish tax ripoff nov   at  am et by tim mullaney alkermes shares rise on schizophrenia drug approval oct   at  pm et by wallace witkowski charting the us markets’ next tests aug   at  am et by michael ashbaugh transports diverge sp  stays the course jun   at  am et by michael ashbaugh sp  traverses bullish range jun   at  am et by michael ashbaugh alkermes stock price target cut to  from  at citigroup mar   at  am et by tomi kilgore alkermes downgraded to neutral from buy at citigroup mar   at  am et by tomi kilgore how to make money with smallcap stocks mar   at  pm et by paul a merriman alkermes to discontinue developing pain treatment feb   at  am et  european companies benefiting from a weak euro jan   at  am et by philip van doorn three top picks in smaller pharma alkermes alder biopharmaceuticals and aimmune are favorites and each has important catalysts coming up may   at  am et on barrons online alkermes shares surge on favorable data for depression drug oct   at  pm et on the wall street journal three biotech q reports hold potential jul   at  am et on barrons fda warns of rare impulse reactions to abilify medication may   at  pm et on the wall street journal five pharma picks for another volatile year jan   at  pm et on barrons alkermes depression drug disappoints in trials jan   at  pm et on the wall street journal biotech faces new trial with alkermes stumble jan   at  am et on the wall street journal stocks to watch verizon fireeye kinder morgan southwest jan   at  am et on the wall street journal fda approves alkermes’ schizophrenia treatment aristada oct   at  pm et on the wall street journal best us pharma picks big and small may   at  am et on barrons stocks to watch apple gm mcdonald’s mar   at  am et on the wall street journal pharmalot pharmalittle good morning we’re reading about gilead glaxo and lots more mar   at  am et on the wall street journal alkermes to sell georgia facility paindrug rights to recro pharma mar   at  am et on the wall street journal up and down the ladder the latest comings  goings at alkermes charles river labs and… feb   at  am et on the wall street journal stocks to watch comcast home depot macy’s feb   at  am et on the wall street journal alkermes to discontinue development of pain treatment feb   at  am et on the wall street journal alkermes schizophrenia drug shows less weight gain jan   at  pm et on the wall street journal stocks to watch eli lilly monsanto jc penney jan   at  am et on the wall street journal pharma favorites to stand the trials of  dec   at  pm et on barrons three ways investors can play the inversion boom jul   at  pm et on the wall street journal recent news other news press releases q biotech catalyst watch phase  data releases part  q biotech catalyst watch phase  data releases part  jul   at  am et on seeking alpha alkermes preliminary phase  data leaves a welcomed impression alkermes preliminary phase  data leaves a welcomed impression jul   at  pm et on seeking alpha what markets are really looking for in alkermes schizophrenia drug what markets are really looking for in alkermes schizophrenia drug jul   at  pm et on gurufocuscom attention biotech investors keep your date with july pdufa actiondays attention biotech investors keep your date with july pdufa actiondays jul   at  am et on benzingacom biotech stock roundup cara plunges on study data regulatory updates  more key highlights in the biotech sector include mixed data from cara cara and regulatory updates from companies like biomarin jul   at  am et on zackscom biotech forum daily digest  biotech fritters away some gains  fda calendar events in july biotech forum daily digest  biotech fritters away some gains  fda calendar events in july jul   at  am et on seeking alpha alkermes presents phase iii data on schizophrenia candidate alkermes plc alks announced positive preliminary topline results from a phase iii study enlighten evaluating its schizophrenia candidate alks  jul   at  am et on zackscom alkermes data dont enlighten alkermes data dont enlighten jun   at  pm et on seeking alpha alkermes antipsychotic candidate alks  successful in latestage schizophrenia study but weight gain may be issue shares down  after hours alkermes antipsychotic candidate alks  successful in latestage schizophrenia study but weight gain may be issue shares down  after hours jun   at  pm et on seeking alpha  outperforming stocks with rising prices  outperforming stocks with rising prices jun   at  pm et on gurufocuscom minerva on track to initiate phase iii schizophrenia study minerva neurosciences inc nerv announced that it is on track to begin phase iii studies on its key schizophrenia pipeline candidate min in the second half of this year as planned jun   at  am et on zackscom alkermes may have lucky investors doing a happy jig alkermes may have lucky investors doing a happy jig jun   at  am et on seeking alpha alkermes commences phase iii study for schizophrenia drug alkermes plc alks announced that it initiated a phase iii study enlightenearly on experimental candidate alks  jun   at  am et on zackscom top analyst upgrades and downgrades cheniere coned foot locker shopify tesla veeco zoetis and many more the top analyst upgrades downgrades and other research calls from tuesday include cheniere energy consolidation edison foot locker shopify tesla veeco instruments and zoetis jun   at  am et on wallstcom premarket analyst action  healthcare premarket analyst action  healthcare jun   at  am et on seeking alpha alkermes looks to capitalize on opioid epidemic through aggressive lobbying alkermes looks to capitalize on opioid epidemic through aggressive lobbying jun   at  am et on benzingacom alkermes initiates latestage study of mdd candidate alks  alkermes initiates latestage study of mdd candidate alks  jun   at  am et on seeking alpha alkermes gets fda nod for two month dose of aristada alkermes plc alks announced that the fda has approved twomonth aristada aripiprazole lauroxil extendedrelease injectable suspension for the treatment of schizophrenia jun   at  am et on zackscom alkermes announces initiation of phase  study of alks  in young adult patients alkermes announces initiation of phase  study of alks  in young adult patients jun   at  am et on seeking alpha key fda events to watch out for in jun  companies like portola ptla are awaiting key fda decisions this month which could send their stocks soaring in case of a positive response jun   at  am et on zackscom alkermes to host conference call to discuss second quarter  financial results alkermes to host conference call to discuss second quarter  financial results jul   at  pm et on businesswire  bzx technical reports on drug delivery equities  petmed express adamis pharma delcath systems and alkermes technical reports on drug delivery equities  petmed express adamis pharma delcath systems and alkermes jul   at  am et on pr newswire  prf alkermes announces positive preliminary topline results from phase  antipsychotic efficacy study of alks  for treatment of schizophrenia alkermes announces positive preliminary topline results from phase  antipsychotic efficacy study of alks  for treatment of schizophrenia jun   at  pm et on businesswire  bzx alkermes announces initiation of study  for alks  for treatment of major depressive disorder alkermes announces initiation of study  for alks  for treatment of major depressive disorder jun   at  am et on businesswire  bzx alkermes to present at goldman sachs th annual global healthcare conference alkermes to present at goldman sachs th annual global healthcare conference jun   at  pm et on businesswire  bzx alkermes announces initiation of phase  study of alks  in young adult patients alkermes announces initiation of phase  study of alks  in young adult patients jun   at  am et on businesswire  bzx fda approves twomonth aristada® for treatment of schizophrenia fda approves twomonth aristada® for treatment of schizophrenia jun   at  am et on businesswire  bzx alkermes’ corporate presentation to be webcast at the jefferies healthcare conference alkermes’ corporate presentation to be webcast at the jefferies healthcare conference may   at  pm et on businesswire  bzx alkermes appoints craig hopkinson md as chief medical officer and senior vice president clinical development and medical affairs alkermes appoints craig hopkinson md as chief medical officer and senior vice president clinical development and medical affairs may   at  am et on businesswire  bzx research reports coverage on drug delivery stocks  valeant pharma delcath systems alkermes and adamis pharma research reports coverage on drug delivery stocks  valeant pharma delcath systems alkermes and adamis pharma may   at  am et on pr newswire  prf alkermes to present data on alks  at upcoming society of biological psychiatry annual meeting alkermes to present data on alks  at upcoming society of biological psychiatry annual meeting may   at  pm et on businesswire  bzx blog coverage alkermes announces completion of patient enrolment in alks  study for the treatment of schizophrenia blog coverage alkermes announces completion of patient enrolment in alks  study for the treatment of schizophrenia may   at  am et on accesswire alkermes plc reports first quarter  financial results alkermes plc reports first quarter  financial results apr   at  am et on businesswire  bzx alkermes’ corporate presentation to be webcast at the deutsche bank nd annual health care conference apr   at  pm et on businesswire  bzx alkermes to host conference call to discuss first quarter  financial results apr   at  pm et on businesswire  bzx research reports initiation on healthcare stocks  valeant pharma delcath systems alkermes and amphastar pharma apr   at  am et on pr newswire  prf us substance abuse treatment market to touch us billion by  awareness programs initiated by treatment providers to drive growth reports tmr mar   at  am et on pr newswire  prf alkermes to present preclinical data on alks  at the american association for cancer research annual meeting mar   at  am et on businesswire  bzx alkermes to present data on twomonth dosing option of aristada® at th international congress on schizophrenia research mar   at  am et on businesswire  bzx alkermes initiates phase  gastrointestinal tolerability study of alks  for treatment of multiple sclerosis mar   at  am et on businesswire  bzx alkermes plc alkermes plc is a biopharmaceutical company it engages in the development manufacturing and distribution of medicines the company was founded on may   and is headquartered in dublin ireland see full profile analyst ratings sell under hold over buy number of ratings  full ratings your cheat sheet for q biotech earnings apr   at  pm et on benzingacom recros latestage iv meloxicam trial results rocket stock skyward nov   at  am et on benzingacom jpmorgan upgrades alkermes as the company adds to its already valuable portfolio oct   at  pm et on benzingacom competitors name chg  market cap acorda therapeutics inc  b astrazeneca plc adr  b novartis ag adr  b bristolmyers squibb co  b johnson  johnson  b competitor data provided by partner content trending tickers powered by amd  x  dwt  aks  t  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stocks index  markets index bulletin investor alert tokyo markets close in currencies europe markets london markets stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pdoes your child have a question there’s a smart toy for that phouse votes to prevent disgruntled customers from being able to sue their bank pone depressing reason millions of people are locked out of the american dream pwhat everyone can learn from jared kushner’s ad hoc approach to meetings pone version of gop healthcare bills fails in senate vote pgeorge clooney and angelina jolie’s directorial projects could be the most soughtafter tickets at tiff pjohn mccain gives trump a win then gives senate an earful ppaypal earnings partnerships help but are benefits already priced in pamd puts intel in the crosshairs with fastandcheap threadripper chip pamd earnings give investors what they wanted now it must deliver phouse passes bill hitting russia with new sanctions pwsj interview trump doesnt rule out firing sessions pformer trump campaign chief manafort strikes deal to avoid public testimony pthis quant pro and card counter says gambling can make you a better investor pbitcoin digital currencies retreat from records pthis is what it will take for bitcoin to become a legit currency pemerging markets fund manager favors bangladesh and kenya and avoids korea and taiwan puss thunderbolt fires warning shots at iranian vessel in gulf phere’s one trump fan who might make you some money pchegg shares sink after secondquarter loss loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert tokyo markets close in currencies europe markets london markets stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pdoes your child have a question there’s a smart toy for that phouse votes to prevent disgruntled customers from being able to sue their bank pone depressing reason millions of people are locked out of the american dream pwhat everyone can learn from jared kushner’s ad hoc approach to meetings pone version of gop healthcare bills fails in senate vote pgeorge clooney and angelina jolie’s directorial projects could be the most soughtafter tickets at tiff pjohn mccain gives trump a win then gives senate an earful ppaypal earnings partnerships help but are benefits already priced in pamd puts intel in the crosshairs with fastandcheap threadripper chip pamd earnings give investors what they wanted now it must deliver phouse passes bill hitting russia with new sanctions pwsj interview trump doesnt rule out firing sessions pformer trump campaign chief manafort strikes deal to avoid public testimony pthis quant pro and card counter says gambling can make you a better investor pbitcoin digital currencies retreat from records pthis is what it will take for bitcoin to become a legit currency pemerging markets fund manager favors bangladesh and kenya and avoids korea and taiwan puss thunderbolt fires warning shots at iranian vessel in gulf phere’s one trump fan who might make you some money pchegg shares sink after secondquarter loss loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert tokyo markets close in currencies europe markets london markets stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pdoes your child have a question there’s a smart toy for that phouse votes to prevent disgruntled customers from being able to sue their bank pone depressing reason millions of people are locked out of the american dream pwhat everyone can learn from jared kushner’s ad hoc approach to meetings pone version of gop healthcare bills fails in senate vote pgeorge clooney and angelina jolie’s directorial projects could be the most soughtafter tickets at tiff pjohn mccain gives trump a win then gives senate an earful ppaypal earnings partnerships help but are benefits already priced in pamd puts intel in the crosshairs with fastandcheap threadripper chip pamd earnings give investors what they wanted now it must deliver phouse passes bill hitting russia with new sanctions pwsj interview trump doesnt rule out firing sessions pformer trump campaign chief manafort strikes deal to avoid public testimony pthis quant pro and card counter says gambling can make you a better investor pbitcoin digital currencies retreat from records pthis is what it will take for bitcoin to become a legit currency pemerging markets fund manager favors bangladesh and kenya and avoids korea and taiwan puss thunderbolt fires warning shots at iranian vessel in gulf phere’s one trump fan who might make you some money pchegg shares sink after secondquarter loss loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  alks stock price  alkermes plc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers fcx  nem  rrc  cat  stx  ipg  mu  wat  latest newsall times eastern p updated does your child have a question there’s a smart toy for that p updated house votes to prevent disgruntled customers from being able to sue their bank p updated one depressing reason millions of people are locked out of the american dream p updated what everyone can learn from jared kushner’s ad hoc approach to meetings p one version of gop healthcare bills fails in senate vote p updated george clooney and angelina jolie’s directorial projects could be the most soughtafter tickets at tiff p john mccain gives trump a win then gives senate an earful p updated paypal earnings partnerships help but are benefits already priced in p updated amd puts intel in the crosshairs with fastandcheap threadripper chip p amd earnings give investors what they wanted now it must deliver to be replaced home investing quotes stocks united states alks overview compare quotes stock screener earnings calendar sectors nasdaq alks us nasdaq join td ameritrade find a broker alkermes plc watchlist createalksalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones opinion what to do when your biotechnology stock gets hit by takeover rumors may   at  pm et by michael brush ‘super bowl’ of health care has questions about trump and drug prices but no answers jan   at  am et by emma court alkermes upgraded to overweight from neutral at jp morgan oct   at  am et by tomi kilgore alkermes stock price target raised to  from  at jp morgan oct   at  am et by tomi kilgore alkermes shares soar more than  after depression drug results oct   at  pm et by wallace witkowski breaking alkermes shares surge  after promising depression drug data oct   at  pm et by wallace witkowski opinion biotech stocks have plenty of catalysts around the corner sep   at  pm et by michael brush alkermes shares plunge after drug misses trial goals jan   at  am et by emma court alkermes stock plunges  premarket after disappointing drug trial results jan   at  am et by tomi kilgore charting the sp ’s precarious posture dec   at  am et by michael ashbaugh opinion how to stop pfizer’s fauxirish tax ripoff nov   at  am et by tim mullaney alkermes shares rise on schizophrenia drug approval oct   at  pm et by wallace witkowski charting the us markets’ next tests aug   at  am et by michael ashbaugh transports diverge sp  stays the course jun   at  am et by michael ashbaugh sp  traverses bullish range jun   at  am et by michael ashbaugh alkermes stock price target cut to  from  at citigroup mar   at  am et by tomi kilgore alkermes downgraded to neutral from buy at citigroup mar   at  am et by tomi kilgore how to make money with smallcap stocks mar   at  pm et by paul a merriman alkermes to discontinue developing pain treatment feb   at  am et  european companies benefiting from a weak euro jan   at  am et by philip van doorn three top picks in smaller pharma alkermes alder biopharmaceuticals and aimmune are favorites and each has important catalysts coming up may   at  am et on barrons online alkermes shares surge on favorable data for depression drug oct   at  pm et on the wall street journal three biotech q reports hold potential jul   at  am et on barrons fda warns of rare impulse reactions to abilify medication may   at  pm et on the wall street journal five pharma picks for another volatile year jan   at  pm et on barrons alkermes depression drug disappoints in trials jan   at  pm et on the wall street journal biotech faces new trial with alkermes stumble jan   at  am et on the wall street journal stocks to watch verizon fireeye kinder morgan southwest jan   at  am et on the wall street journal fda approves alkermes’ schizophrenia treatment aristada oct   at  pm et on the wall street journal best us pharma picks big and small may   at  am et on barrons stocks to watch apple gm mcdonald’s mar   at  am et on the wall street journal pharmalot pharmalittle good morning we’re reading about gilead glaxo and lots more mar   at  am et on the wall street journal alkermes to sell georgia facility paindrug rights to recro pharma mar   at  am et on the wall street journal up and down the ladder the latest comings  goings at alkermes charles river labs and… feb   at  am et on the wall street journal stocks to watch comcast home depot macy’s feb   at  am et on the wall street journal alkermes to discontinue development of pain treatment feb   at  am et on the wall street journal alkermes schizophrenia drug shows less weight gain jan   at  pm et on the wall street journal stocks to watch eli lilly monsanto jc penney jan   at  am et on the wall street journal pharma favorites to stand the trials of  dec   at  pm et on barrons three ways investors can play the inversion boom jul   at  pm et on the wall street journal recent news other news press releases q biotech catalyst watch phase  data releases part  q biotech catalyst watch phase  data releases part  jul   at  am et on seeking alpha alkermes preliminary phase  data leaves a welcomed impression alkermes preliminary phase  data leaves a welcomed impression jul   at  pm et on seeking alpha what markets are really looking for in alkermes schizophrenia drug what markets are really looking for in alkermes schizophrenia drug jul   at  pm et on gurufocuscom attention biotech investors keep your date with july pdufa actiondays attention biotech investors keep your date with july pdufa actiondays jul   at  am et on benzingacom biotech stock roundup cara plunges on study data regulatory updates  more key highlights in the biotech sector include mixed data from cara cara and regulatory updates from companies like biomarin jul   at  am et on zackscom biotech forum daily digest  biotech fritters away some gains  fda calendar events in july biotech forum daily digest  biotech fritters away some gains  fda calendar events in july jul   at  am et on seeking alpha alkermes presents phase iii data on schizophrenia candidate alkermes plc alks announced positive preliminary topline results from a phase iii study enlighten evaluating its schizophrenia candidate alks  jul   at  am et on zackscom alkermes data dont enlighten alkermes data dont enlighten jun   at  pm et on seeking alpha alkermes antipsychotic candidate alks  successful in latestage schizophrenia study but weight gain may be issue shares down  after hours alkermes antipsychotic candidate alks  successful in latestage schizophrenia study but weight gain may be issue shares down  after hours jun   at  pm et on seeking alpha  outperforming stocks with rising prices  outperforming stocks with rising prices jun   at  pm et on gurufocuscom minerva on track to initiate phase iii schizophrenia study minerva neurosciences inc nerv announced that it is on track to begin phase iii studies on its key schizophrenia pipeline candidate min in the second half of this year as planned jun   at  am et on zackscom alkermes may have lucky investors doing a happy jig alkermes may have lucky investors doing a happy jig jun   at  am et on seeking alpha alkermes commences phase iii study for schizophrenia drug alkermes plc alks announced that it initiated a phase iii study enlightenearly on experimental candidate alks  jun   at  am et on zackscom top analyst upgrades and downgrades cheniere coned foot locker shopify tesla veeco zoetis and many more the top analyst upgrades downgrades and other research calls from tuesday include cheniere energy consolidation edison foot locker shopify tesla veeco instruments and zoetis jun   at  am et on wallstcom premarket analyst action  healthcare premarket analyst action  healthcare jun   at  am et on seeking alpha alkermes looks to capitalize on opioid epidemic through aggressive lobbying alkermes looks to capitalize on opioid epidemic through aggressive lobbying jun   at  am et on benzingacom alkermes initiates latestage study of mdd candidate alks  alkermes initiates latestage study of mdd candidate alks  jun   at  am et on seeking alpha alkermes gets fda nod for two month dose of aristada alkermes plc alks announced that the fda has approved twomonth aristada aripiprazole lauroxil extendedrelease injectable suspension for the treatment of schizophrenia jun   at  am et on zackscom alkermes announces initiation of phase  study of alks  in young adult patients alkermes announces initiation of phase  study of alks  in young adult patients jun   at  am et on seeking alpha key fda events to watch out for in jun  companies like portola ptla are awaiting key fda decisions this month which could send their stocks soaring in case of a positive response jun   at  am et on zackscom alkermes to host conference call to discuss second quarter  financial results alkermes to host conference call to discuss second quarter  financial results jul   at  pm et on businesswire  bzx technical reports on drug delivery equities  petmed express adamis pharma delcath systems and alkermes technical reports on drug delivery equities  petmed express adamis pharma delcath systems and alkermes jul   at  am et on pr newswire  prf alkermes announces positive preliminary topline results from phase  antipsychotic efficacy study of alks  for treatment of schizophrenia alkermes announces positive preliminary topline results from phase  antipsychotic efficacy study of alks  for treatment of schizophrenia jun   at  pm et on businesswire  bzx alkermes announces initiation of study  for alks  for treatment of major depressive disorder alkermes announces initiation of study  for alks  for treatment of major depressive disorder jun   at  am et on businesswire  bzx alkermes to present at goldman sachs th annual global healthcare conference alkermes to present at goldman sachs th annual global healthcare conference jun   at  pm et on businesswire  bzx alkermes announces initiation of phase  study of alks  in young adult patients alkermes announces initiation of phase  study of alks  in young adult patients jun   at  am et on businesswire  bzx fda approves twomonth aristada® for treatment of schizophrenia fda approves twomonth aristada® for treatment of schizophrenia jun   at  am et on businesswire  bzx alkermes’ corporate presentation to be webcast at the jefferies healthcare conference alkermes’ corporate presentation to be webcast at the jefferies healthcare conference may   at  pm et on businesswire  bzx alkermes appoints craig hopkinson md as chief medical officer and senior vice president clinical development and medical affairs alkermes appoints craig hopkinson md as chief medical officer and senior vice president clinical development and medical affairs may   at  am et on businesswire  bzx research reports coverage on drug delivery stocks  valeant pharma delcath systems alkermes and adamis pharma research reports coverage on drug delivery stocks  valeant pharma delcath systems alkermes and adamis pharma may   at  am et on pr newswire  prf alkermes to present data on alks  at upcoming society of biological psychiatry annual meeting alkermes to present data on alks  at upcoming society of biological psychiatry annual meeting may   at  pm et on businesswire  bzx blog coverage alkermes announces completion of patient enrolment in alks  study for the treatment of schizophrenia blog coverage alkermes announces completion of patient enrolment in alks  study for the treatment of schizophrenia may   at  am et on accesswire alkermes plc reports first quarter  financial results alkermes plc reports first quarter  financial results apr   at  am et on businesswire  bzx alkermes’ corporate presentation to be webcast at the deutsche bank nd annual health care conference apr   at  pm et on businesswire  bzx alkermes to host conference call to discuss first quarter  financial results apr   at  pm et on businesswire  bzx research reports initiation on healthcare stocks  valeant pharma delcath systems alkermes and amphastar pharma apr   at  am et on pr newswire  prf us substance abuse treatment market to touch us billion by  awareness programs initiated by treatment providers to drive growth reports tmr mar   at  am et on pr newswire  prf alkermes to present preclinical data on alks  at the american association for cancer research annual meeting mar   at  am et on businesswire  bzx alkermes to present data on twomonth dosing option of aristada® at th international congress on schizophrenia research mar   at  am et on businesswire  bzx alkermes initiates phase  gastrointestinal tolerability study of alks  for treatment of multiple sclerosis mar   at  am et on businesswire  bzx alkermes plc alkermes plc is a biopharmaceutical company it engages in the development manufacturing and distribution of medicines the company was founded on may   and is headquartered in dublin ireland see full profile analyst ratings sell under hold over buy number of ratings  full ratings your cheat sheet for q biotech earnings apr   at  pm et on benzingacom recros latestage iv meloxicam trial results rocket stock skyward nov   at  am et on benzingacom jpmorgan upgrades alkermes as the company adds to its already valuable portfolio oct   at  pm et on benzingacom competitors name chg  market cap acorda therapeutics inc  b astrazeneca plc adr  b novartis ag adr  b bristolmyers squibb co  b johnson  johnson  b competitor data provided by partner content trending tickers powered by amd  x  dwt  aks  t  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience alksnasdaq gs stock quote  alkermes plc  bloomberg markets error could not add to watchlist x  watchlist alkermes plc alksus nasdaq gs usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap b usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases  alkermes alks ceo pops says biotech stocks recovered quite a bit postelection  the street  alkermes depression drug shows good results alks  investopedia  alkermes alks stock soars on trial results upgrades  the street  analysts actions  alkermes chesapeake microsoft yahoo and more  the street there are currently no news stories for this ticker please check back later  alkermes to host conference call to discuss second quarter  financial results  prostate cancer pipeline h  therapeutic key players v biosciences inc sc ag actinium pharmaceuticals inc and advaxis  multiple sclerosis drugs and therapeutic pipeline review h  research available at rnr market research  alkermes announces positive preliminary topline results from phase  antipsychotic efficacy study of alks  for treatment of  bio elects john maraganore phd as new chair  alkermes announces initiation of study  for alks  for treatment of major depressive disorder  alkermes to present at goldman sachs th annual global healthcare conference  alkermes announces initiation of phase  study of alks  in young adult patients  fda approves twomonth aristada® for treatment of schizophrenia  schizophrenia pipeline therapeutics development drug profiles and key players market analysis report now available at there are currently no press releases for this ticker please check back later profile alkermes plc researches pharmaceuticals the company develops treatments for central nervous system disorders such as addiction schizophrenia and depression and diabetes address connaught house burlington roaddublin  d cyireland phone  website wwwalkermescom executives board members richard f pops chairmanceo shane m cooke president kathryn l biberstein exec vpchief administrative ofcr  chief risk ofcr elliot w ehrich exec vpresearch  dev james m frates jim senior vpcfotreasurer show more microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft velocionet velocionet next generation plcs small inexpensive easytouse plcs programmed with vbuilder the industries most innovative programming software free download store ace branch embedded simulators software vbuilder vfactory indusoft tutorials  items –  account ace powerful pocketsized plcs branch lots of io where you need it better smaller cheaper branch out lots of io distributed processing awesome plc software and its free  x  x  worlds smallest plc starting at  lowest cost plc anywhere gets io where its needed connect up to  units up to  io points io with full plc power embed subroutines in them all the benefits of ace plus introducing ace fits most anywhere tailored to your needs io options  io points  io points  io points analog input options  volts  mamps  volts termination options pluggable spring type larger screwtype relay optocoupled mounting options din rail bolt mount super strong adhesive made for motion every ace and branch plc includes stepping motor pulsed output up to khz high speed counter for pulse or quadrature inputs up to  khz servo control  led intensity control every digital output can produce it’s own pulsewidth modulation pwm signal as well as software counters ramps and pids programmed with software youll enjoy using  graphically program in flow charts andor ladder logic to rapidly create custom applications we simplified the instruction set our function set is comprehensive easy to use and powerful no hunting for features vbuilder’s layout keeps the tools and information you need in plain view warnings and errors are presented in real time so there are no surprises at build tag based plcs are easier to use than address based ones but typically cost hundreds of dollars our entire line starting at  is tag based innovative features we’ve developed some great features to help you get things done quicker and more reliably subroutines break projects up into manageable chunks and allow program reuse objects isolate data and create logic components to greatly improve development efficiency maintainability and reliability linked subroutines specify that multiple subroutines should use the same objects maybe you’ve got an initialization routine you’d like in one subroutine and a process you want in another they can share an object so you don’t have to pass data between the two view your data and create operator controls with awesome free hmi we’re serious about delivering the easiest to use most productive plc software we could go on about our features but seeing is believing so check out our vbuilder page vfactory page or download vbuilder and vfactory theyre free meet branch expansion has a vlink input port instead of usb expansions are otherwise physically identical to branch main your sensors and actuators are branched out your plc should branch with them branchs unique structure beats backplane and brick systems at getting io where it’s need helping you run shorter wires and keep an organized system smarter io expansion units have full plc processing power and memory vbuilder’s power shines with branch put subroutines inside of io units to focus processing where it’s most needed debug your entire branch system as a unit no need to debug one processor at a time lets you view realtime data for your entire system plc programming should be fun we’ve got engaging tutorials to get you up to speed on our plcs and more are on the way whether you’re new to plcs or just new to us we want your learning experience to be enjoyable the tutorials aren’t boring or difficult to follow we promise free connector tool for a limited time only we’re giving away a free connector tool with every order every order over  ships free  of our plcs qualify for free us standard shipping we also ship to canada and mexico for   satisfaction guarantee shop with confidence knowing that you are free to return any product for a full  days after purchase and receive a full refund choose your adventure about us  contact us  store  velocio networks  to   privacy policy  terms of service ﻿ alkermes – a global biopharmaceutical company home contact us site map about us about us about alkermes our company message from the ceo locations leadership management team board of directors collaborations strategic partners products products products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies research  development research  development research  development rd overview our rd approach pipeline technology platforms manufacturing other information clinical trials expanded access responsibility responsibility responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors investors investors corporate overview press releases investor events stock information sec filings annual reports financials snapshot trading statistics other information email alerts news  events news  events news  events press releases media kit careers careers careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer job opportunities jobs overview field sales roles all available roles science with a purpose alkermes applies its scientific expertise and technological knowhow to develop innovative medicines designed to help patients with serious chronic conditions better manage their disease our company latest news alkermes to host conference call to discuss second quarter  financial results read more alkermes announces positive preliminary topline results from phase  antipsychotic efficacy study of alks  for treatment of schizophrenia read more alkermes announces initiation of study  for alks  for treatment of major depressive disorder read more investors learn more pipeline see our approach working at alkermes join our team you are now leaving alkermescom about us our company message from the ceo locations management team board of directors strategic partners products products overview aristada® vivitrol® us products using alkermes technologies eu products using alkermes technologies wholesaler and purchasing information research  development rd overview our rd approach pipeline technology platforms manufacturing clinical trials expanded access responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors corporate overview press releases investor events stock information sec filings annual reports snapshot trading statistics email alerts news  events press releases media kit careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer jobs overview field sales roles all available roles  alkermes all rights reserved terms of use privacy policy alkermes company  wikipedia alkermes company from wikipedia the free encyclopedia jump to navigation search alkermes plc type public nasdaq alks industry biotechnology headquarters dublin ireland key people richard pops ceo revenue us million operating income us million net income us million total assets us million total equity us million number of employees  website wwwalkermescom alkermes plc is a biopharmaceutical company that focuses on central nervous system cns diseases the company is the result of a merger in september  between alkermes inc and elan drug technologies edt the former drug formulation and manufacturing division of élan corporation plc the company is headquartered in dublin and has an rd center in waltham massachusetts and manufacturing facilities in athlone ireland and wilmington ohio productsedit alkermes has more than  commercial drug products and candidates that address serious and chronic diseases such as addiction schizophrenia diabetes and depression among these products five are primary to the company risperidone longacting injection generic for risperdal consta for schizophrenia and bipolar  disorder paliperidone palmitate generic for invega sustenna in the us xeplion in europe for schizophrenia aminopyridine generic for ampyra in the us fampyra in europe to improve walking in patients with multiple sclerosis naltrexone for extendedrelease injectable suspension generic for vivitrol for alcohol and opioid dependence and exenatide extendedrelease for injectable suspension generic for bydureon for the treatment of type  diabetes bydureon is a onceweekly extendedrelease form of the drug exenatide byetta and was developed through a partnership between amylin pharmaceuticals alkermes and eli lilly it is approved in europe and the us alks a κopioid receptor antagonist is a nextgeneration novel antidepressant which is under development by alkermes for treatmentresistant depression referencesedit  a b robert weisman  may  alkermes to buy irish drug maker boston globe retrieved  october    alkermes alks quarterly report wikiinvest  retrieved  october    alkermes reels in elans drug technology business forbescom  may  retrieved  october    zacks equity research “positive data on risperdal consta” yahoo finance march    john m grohol “risperdal consta approved for bipolar” psychcentralcom may    cole petrochko “fda okays first monthly antipsychotic drug” medpage today august    matt jarzemsky “johnson  johnson gets european approval for schizophrenia shot” the wall street journal march    susan jeffrey “fda approves dalfampridine to improve walking in multiple sclerosis” medscape medical news january    toni clarke “europe backs acorda biogen drug in change of tack” reuters may    miranda hitti “fda oks new drug to treat alcoholism” webmd april    rita rubin “fda oks vivitrol to treat heroin narcotic addictions” usa today october    denise mann weekly shot gets fda nod for type  diabetes webmd january    harrison charlotte  trial watch opioid receptor blocker shows promise in phase ii depression trial nature reviews drug discovery   – issn  pmid  doinrd  v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlealkermescompanyoldid categories pharmaceutical companies of irelandcompanies in the nasdaq biotechnology indexcompanies based in dublin citycompanies listed on nasdaqlife sciences industry navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی  語   한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info ﻿ alkermes – a global biopharmaceutical company home contact us site map about us about us about alkermes our company message from the ceo locations leadership management team board of directors collaborations strategic partners products products products products overview united states aristada® vivitrol® us products using alkermes technologies wholesaler and purchasing information european union eu products using alkermes technologies research  development research  development research  development rd overview our rd approach pipeline technology platforms manufacturing other information clinical trials expanded access responsibility responsibility responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors investors investors corporate overview press releases investor events stock information sec filings annual reports financials snapshot trading statistics other information email alerts news  events news  events news  events press releases media kit careers careers careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer job opportunities jobs overview field sales roles all available roles science with a purpose alkermes applies its scientific expertise and technological knowhow to develop innovative medicines designed to help patients with serious chronic conditions better manage their disease our company latest news alkermes to host conference call to discuss second quarter  financial results read more alkermes announces positive preliminary topline results from phase  antipsychotic efficacy study of alks  for treatment of schizophrenia read more alkermes announces initiation of study  for alks  for treatment of major depressive disorder read more investors learn more pipeline see our approach working at alkermes join our team you are now leaving alkermescom about us our company message from the ceo locations management team board of directors strategic partners products products overview aristada® vivitrol® us products using alkermes technologies eu products using alkermes technologies wholesaler and purchasing information research  development rd overview our rd approach pipeline technology platforms manufacturing clinical trials expanded access responsibility alkermes corporate giving investigator initiated trials educational grants patient engagement support alkermes inspiration grants™ investors corporate overview press releases investor events stock information sec filings annual reports snapshot trading statistics email alerts news  events press releases media kit careers working together our core values total rewards meet our employees recruiting agencies equal opportunity employer jobs overview field sales roles all available roles  alkermes all rights reserved terms of use privacy policy alkermes company  wikipedia alkermes company from wikipedia the free encyclopedia jump to navigation search alkermes plc type public nasdaq alks industry biotechnology headquarters dublin ireland key people richard pops ceo revenue us million operating income us million net income us million total assets us million total equity us million number of employees  website wwwalkermescom alkermes plc is a biopharmaceutical company that focuses on central nervous system cns diseases the company is the result of a merger in september  between alkermes inc and elan drug technologies edt the former drug formulation and manufacturing division of élan corporation plc the company is headquartered in dublin and has an rd center in waltham massachusetts and manufacturing facilities in athlone ireland and wilmington ohio productsedit alkermes has more than  commercial drug products and candidates that address serious and chronic diseases such as addiction schizophrenia diabetes and depression among these products five are primary to the company risperidone longacting injection generic for risperdal consta for schizophrenia and bipolar  disorder paliperidone palmitate generic for invega sustenna in the us xeplion in europe for schizophrenia aminopyridine generic for ampyra in the us fampyra in europe to improve walking in patients with multiple sclerosis naltrexone for extendedrelease injectable suspension generic for vivitrol for alcohol and opioid dependence and exenatide extendedrelease for injectable suspension generic for bydureon for the treatment of type  diabetes bydureon is a onceweekly extendedrelease form of the drug exenatide byetta and was developed through a partnership between amylin pharmaceuticals alkermes and eli lilly it is approved in europe and the us alks a κopioid receptor antagonist is a nextgeneration novel antidepressant which is under development by alkermes for treatmentresistant depression referencesedit  a b robert weisman  may  alkermes to buy irish drug maker boston globe retrieved  october    alkermes alks quarterly report wikiinvest  retrieved  october    alkermes reels in elans drug technology business forbescom  may  retrieved  october    zacks equity research “positive data on risperdal consta” yahoo finance march    john m grohol “risperdal consta approved for bipolar” psychcentralcom may    cole petrochko “fda okays first monthly antipsychotic drug” medpage today august    matt jarzemsky “johnson  johnson gets european approval for schizophrenia shot” the wall street journal march    susan jeffrey “fda approves dalfampridine to improve walking in multiple sclerosis” medscape medical news january    toni clarke “europe backs acorda biogen drug in change of tack” reuters may    miranda hitti “fda oks new drug to treat alcoholism” webmd april    rita rubin “fda oks vivitrol to treat heroin narcotic addictions” usa today october    denise mann weekly shot gets fda nod for type  diabetes webmd january    harrison charlotte  trial watch opioid receptor blocker shows promise in phase ii depression trial nature reviews drug discovery   – issn  pmid  doinrd  v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlealkermescompanyoldid categories pharmaceutical companies of irelandcompanies in the nasdaq biotechnology indexcompanies based in dublin citycompanies listed on nasdaqlife sciences industry navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view alkermes company  wikipedia alkermes company from wikipedia the free encyclopedia jump to navigation search alkermes plc type public nasdaq alks industry biotechnology headquarters dublin ireland key people richard pops ceo revenue us million operating income us million net income us million total assets us million total equity us million number of employees  website wwwalkermescom alkermes plc is a biopharmaceutical company that focuses on central nervous system cns diseases the company is the result of a merger in september  between alkermes inc and elan drug technologies edt the former drug formulation and manufacturing division of élan corporation plc the company is headquartered in dublin and has an rd center in waltham massachusetts and manufacturing facilities in athlone ireland and wilmington ohio productsedit alkermes has more than  commercial drug products and candidates that address serious and chronic diseases such as addiction schizophrenia diabetes and depression among these products five are primary to the company risperidone longacting injection generic for risperdal consta for schizophrenia and bipolar  disorder paliperidone palmitate generic for invega sustenna in the us xeplion in europe for schizophrenia aminopyridine generic for ampyra in the us fampyra in europe to improve walking in patients with multiple sclerosis naltrexone for extendedrelease injectable suspension generic for vivitrol for alcohol and opioid dependence and exenatide extendedrelease for injectable suspension generic for bydureon for the treatment of type  diabetes bydureon is a onceweekly extendedrelease form of the drug exenatide byetta and was developed through a partnership between amylin pharmaceuticals alkermes and eli lilly it is approved in europe and the us alks a κopioid receptor antagonist is a nextgeneration novel antidepressant which is under development by alkermes for treatmentresistant depression referencesedit  a b robert weisman  may  alkermes to buy irish drug maker boston globe retrieved  october    alkermes alks quarterly report wikiinvest  retrieved  october    alkermes reels in elans drug technology business forbescom  may  retrieved  october    zacks equity research “positive data on risperdal consta” yahoo finance march    john m grohol “risperdal consta approved for bipolar” psychcentralcom may    cole petrochko “fda okays first monthly antipsychotic drug” medpage today august    matt jarzemsky “johnson  johnson gets european approval for schizophrenia shot” the wall street journal march    susan jeffrey “fda approves dalfampridine to improve walking in multiple sclerosis” medscape medical news january    toni clarke “europe backs acorda biogen drug in change of tack” reuters may    miranda hitti “fda oks new drug to treat alcoholism” webmd april    rita rubin “fda oks vivitrol to treat heroin narcotic addictions” usa today october    denise mann weekly shot gets fda nod for type  diabetes webmd january    harrison charlotte  trial watch opioid receptor blocker shows promise in phase ii depression trial nature reviews drug discovery   – issn  pmid  doinrd  v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlealkermescompanyoldid categories pharmaceutical companies of irelandcompanies in the nasdaq biotechnology indexcompanies based in dublin citycompanies listed on nasdaqlife sciences industry navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view data dumps    freebase api deprecated    google developers freebase api deprecated all products sign in send feedback hey there are you maybe looking for firebase instead data dumps the freebase api will be completely shutdown on aug   this page provides access to the last available data dump read more data dumps are a downloadable version of the data in freebase they constitute a snapshot of the data stored in freebase and the schema that structures it and are provided under the same ccby license the freebasewikidata mappings are provided under the cc license freebase triples freebase deleted triples freebasewikidata mappings license citing freebase triples this dataset contains every fact currently in freebase total triples  billion updated weekly data format ntriples rdf license ccby  gb gzip gb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagedate httpwwwworgxmlschemagyearmonth  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagesource httprdffreebasecomnsgxgfm  httprdffreebasecomnsgvjzynm httprdffreebasecomnstypeobjecttype httprdffreebasecomnsmeasurementunitdatedpercentage  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagerate   httprdffreebasecomnsgvjzynm httpwwwworgrdfsyntaxnstype httprdffreebasecomnsmeasurementunitdatedpercentage  if youre writing your own code to parse the rdf dumps its often more efficient to read directly from gzip file rather than extracting the data first and then processing the uncompressed data subject predicate object  note in freebase objects have mids that look like mrkqx in rdf those mids become mrkqx likewise freebase schema like commontopic are written as commontopic the subject is the id of a freebase object it can be a freebase mid ex mrkqx for topics and cvts or a humanreadable id ex commontopic for schema the predicate is always a humanreadable id for a freebase property or a property from a standard rdf vocabulary like rdfs freebase foreign key namespaces are also used as predicates to make it easier to look up keys by namespace the object field may contain a freebase mid for an object or a humanreadable id for schema from freebase or other rdf vocabularies it may also include literal values like strings booleans and numeric values topic descriptions often contain newlines in order to make each triple fit on one line we have escaped newlines with n freebase deleted triples we also provide a dump of triples that have been deleted from freebase over time this is a onetime dump through march  in the future we might consider providing periodic updates of recently deleted triples but at the moment we have no specific timeframe for doing so and are only providing this onetime dump the dump is distributed as a targz file gb compressed gb uncompressed it contains  deleted triples in  files there is no particular meaning to the individual files it is just easier to manipulate several smaller files than one huge file thanks to chun how tan and john giannandrea for making this data release possible total triples  million updated june   data format csv license ccby  gb gzip gb uncompressed download the data format is essentially csv with one important caveat the object field may contain any characters including commas as well as any other reasonable delimiters you could think of however all the other fields are guaranteed not to contain commas so the data can still be parsed unambiguously the columns in the dataset are defined as creationtimestamp unix epoch time in milliseconds creator deletiontimestamp unix epoch time in milliseconds deletor subject mid predicate mid object midliteral languagecode csv usermwclwikipediaenusermwclwikipediaenmrtypeobjectkeywikipediaenben usermwclmusicbrainzuserturtlewaxbotmnncpzmusicrecordingartistmvbfmen usermwclimagesusergardeningbotmwmcommonimagesizemklyen usermwclmusicbrainzusermbzpipelinemergebotmfvvltypeobjecttypecommontopicen usermwclimagesusergardeningbotmxsczcommonlicensedobjectlicensemxben usercontentadministratorusergardeningbotmgkbytypeobjecttypetypecontenten usermwclimagesusergardeningbotmhcommontopicimagemcsen usermwclchefmozuserdeletebotmzcztypeobjectnamela casa rosa mexican restauranten freebasewikidata mappings the data has been created based on the wikidatadump of october   and contains only those links that have at least two common wikipedialinks and not a single disagreeing wikipedialink furthermore the lines are sorted by the number of common wikipedialinks although in turtle this does not really matter total triples m updated october   data format ntriples rdf license cc  mb gzip mb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsmj httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmnrg httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmjgd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmgd httpwwwworgowlsameas httpwwwwikidataorgentityq  license freebase data dumps are provided free of charge for any purpose with regular updates by google they are distributed like freebase itself under the creative commons attribution aka ccby and use is subject to the terms of service the freebasewikidata id mappings are provided under cc and can be used without restrictions citing if youd like to cite these data dumps in a publication you may use google freebase data dumps httpsdevelopersgooglecomfreebasedata month day year or as bibtex bibtex misc except as otherwise noted the content of this page is licensed under the creative commons attribution  license and code samples are licensed under the apache  license for details see our site policies java is a registered trademark of oracle andor its affiliates last updated february   send feedback about this page documentation feedback freebase api deprecated product feedback cancel